Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Nitin Jain, Patrice Chevallier, Hongtao Liu, Gary J. Schiller, Jean-Baptiste Méar, Daniel J. DeAngelo, Kevin J Curran, Stephan Grupp, Andre Baruchel, Marie Balsat, Alexandra LaCroce, Caroline Roudet, Ana B. Korngold, Kathryn J. Newhall, Eric Laille, Daniel J. Lee, Mark G. Frattini, Richard A. Larson, Nicolas Boissel

Blood (2023) 142 (Supplement 1): 4847.

https://doi.org/10.1182/blood-2023-187252

Published: 2023

Journal Articles

Enasidenib vs conventional care in older patients with late-stage mutant- IDH2 relapsed/refractory AML: a randomized phase 3 trial

Blood (2023) 141 (2): 156–167.

https://doi.org/10.1182/blood.2021014901

Published: 2023

Includes: Supplemental data

Journal Articles

OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)

Farhad Ravandi, Hetty E. Carraway, Lilia Taningco, Kimberley Dilley, Eric Laille, Jing Gong, Daniel Lopes de Menezes, Andrew H. Wei

Blood (2021) 138 (Supplement 1): 2314.

https://doi.org/10.1182/blood-2021-147293

Published: 2021

Journal Articles

Phase I/II Multicenter Study of Romidepsin in Japanese Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Blood (2016) 128 (22): 3012.

https://doi.org/10.1182/blood.V128.22.3012.3012

Published: 2016

Journal Articles

CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

Basem M. William, MD, Marcos de Lima, MD, Betul Oran, MD, Richard Champlin, MD, Esperanza B Papadopoulos, MD, Sergio Giralt, MD, Bart L. Scott, MD, Joel Hetzer, PhD, Xiwei Wang, PhD, Eric Laille, MS, Barry S. Skikne, MD, Charles Craddock, MDPhD

Blood (2014) 124 (21): 990.

https://doi.org/10.1182/blood.V124.21.990.990

Published: 2014

Journal Articles

CC-486 in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML): Safety, Tolerability, and Response

Michael R. Savona, MD, Kathryn Kolibaba, MD, Paul Conkling, MD, Edwin C. Kingsley, MD, Carlos Becerra, MD, John Morris, MD, Robert M. Rifkin, MD, Eric Laille, MS, Amy Kellerman, BA, Stacey M. Ukrainskyj, BSN,RN, Qian Dong, MS, Barry S. Skikne, MD

Blood (2014) 124 (21): 4638.

https://doi.org/10.1182/blood.V124.21.4638.4638

Published: 2014

Journal Articles

Extended Dosing of Oral Azacitidine (CC-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule

Eric Laille, MS, Tao Shi, PhD, Guillermo Garcia-Manero, MD, Christopher R. Cogle, MD, Steven D. Gore, MD, Keshava J. Kumar, PhD, Barry S. Skikne, MD, Kyle J. MacBeth, PhD

Blood (2012) 120 (21): 1337.

https://doi.org/10.1182/blood.V120.21.1337.1337

Published: 2012

Journal Articles

A 2-Part Phase I Study in Patients with Solid or Hematologic Malignancies: Dose Proportionality of Subcutaneous (SC) Azacitidine (AZA) and Pharmacokinetics of SC AZA in Patients with Severe Renal Impairment,

Eric Laille, MS, Alain C. Mita, MD, Sanjay Goel, MD, MS, Nashat Y. Gabrail, MD, Joseph Schwarz, MBA, CL Beach, PharmD

Blood (2011) 118 (21): 3480.

https://doi.org/10.1182/blood.V118.21.3480.3480

Published: 2011

Journal Articles

Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML)

Steven D. Gore, MD, Christopher R. Cogle, MD, Barry Skikne, MD, Eric Laille, MS, Tao Shi, PhD, Kyle J. MacBeth, PhD, Heidi Giordano, MA, MBA, Guillermo Garcia-Manero

Blood (2011) 118 (21): 1546.

https://doi.org/10.1182/blood.V118.21.1546.1546

Published: 2011

Journal Articles

Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study

Guillermo Garcia-Manero, MD, Steven D. Gore, MD, Christopher R. Cogle, MD, Elias J. Jabbour, MD, M. Renee Ward, MD, PhD, Kyle J. MacBeth, PhD, Eric Laille, MS, Heidi Giordano, MA, Hagop M. Kantarjian, MD, Barry S. Skikne, MD

Blood (2010) 116 (21): 603.

https://doi.org/10.1182/blood.V116.21.603.603

Published: 2010

Journal Articles

A Comparative Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Azacitidine Following Subcutaneous (SC) and Oral Administration in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML), Results From a Phase 1 Study.

Kyle J MacBeth, Eric Laille, Yuhong Ning, Christopher R. Cogle, MD, Barry Skikne, Steven D. Gore, MD, Guillermo Garcia-Manero, MD, M. Renee Ward, MD, PhD

Blood (2009) 114 (22): 1772.

https://doi.org/10.1182/blood.V114.22.1772.1772

Published: 2009

Journal Articles

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML).

Guillermo Garcia-Manero, MD, Steven D. Gore, MD, Barry Skikne, Christopher R. Cogle, MD, Yuhong Ning, Kyle J MacBeth, Eric Laille, M. Renee Ward, MD, PhD

Blood (2009) 114 (22): 117.

https://doi.org/10.1182/blood.V114.22.117.117

Published: 2009

Journal Articles

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

Guillermo Garcia-Manero, Sarit Assouline, Jorge Cortes, Zeev Estrov, Hagop Kantarjian, Hui Yang, Willie M. Newsome, Wilson H. Miller, Jr, Caroline Rousseau, Ann Kalita, Claire Bonfils, Marja Dubay, Tracy-Ann Patterson, Zuomei Li, Jeffrey M. Besterman, Gregory Reid, Eric Laille, Robert E. Martell, Mark Minden

Blood (2008) 112 (4): 981–989.

https://doi.org/10.1182/blood-2007-10-115873

Published: 2008

Includes: Supplemental data

Journal Articles

Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).

Guillermo Garcia-Manero, MD, Allen S. Yang, MD, Virginia Klimek, MD, Jorge Cortes, MD, Farhad Ravandi, MD, Willie M. Newsome, RN, Julie Dumouchel, Marja Dubay, Zoumei Li, Christiane Maroun, Eric Laille, Hagop Kantarjian, MD, Robert E. Martell, MD, Selina Luger, MD

Blood (2007) 110 (11): 444.

https://doi.org/10.1182/blood.V110.11.444.444

Published: 2007

NARROW

Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Enasidenib vs conventional care in older patients with late-stage mutant- IDH2 relapsed/refractory AML: a randomized phase 3 trial

OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)

Phase I/II Multicenter Study of Romidepsin in Japanese Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

CC-486 in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML): Safety, Tolerability, and Response

Extended Dosing of Oral Azacitidine (CC-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule

A 2-Part Phase I Study in Patients with Solid or Hematologic Malignancies: Dose Proportionality of Subcutaneous (SC) Azacitidine (AZA) and Pharmacokinetics of SC AZA in Patients with Severe Renal Impairment,

Oral Azacitidine (AZA) Activity in Patients with Acute Myelogenous Leukemia (AML)

Evaluation of Oral Azacitidine Using Extended Treatment Schedules: A Phase I Study

A Comparative Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Azacitidine Following Subcutaneous (SC) and Oral Administration in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML), Results From a Phase 1 Study.

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML).

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only